Animal Testing

Elliot Colburn Excerpts

Monday 19th February 2024 Westminster Hall

[Elliot Colburn (Carshalton and Wallington) (Con)]

I beg to move,

That this House has considered e-petitions 633591 and 645885 relating to animal testing and non-animal research methods.

It is a pleasure to serve under your chairmanship, Dame Caroline. On behalf of the Petitions Committee, I would like to introduce two petitions dealing with legislation on animal testing and the promotion of non-animal research methods. I stress that we are here once again—this is becoming an annual debate. That demonstrates the strength of feeling of our constituents and of people across the UK, a nation of animal lovers, that these procedures and processes really must start being brought to an end.

I will start by reading the prayers of the petitions. The first, e-petition 633591, advocates for the ending of animal toxicity tests and the prioritisation of non-animal methods, or NAMs. The petition was started by Maria and closed in September 2023 with 109,378 signatures, including 233 from my Carshalton and Wallington constituency. It argues that NAMs are

“more predictive of human biology, more economically advantageous,”

and prevent animal suffering. E-petition 645885 calls for the banning of the use of dogs for testing and research, citing their cognitive abilities and emotional range. The petition was started by singer-songwriter and actor Will Young, who I am delighted to see in the Public Gallery today. As of now, it has over 30,000 signatures, including 35 from Carshalton and Wallington.

Let me begin with a bit of background information. Animal testing is covered by the Animals (Scientific Procedures) Act 1986, which was amended in 2012 to include cephalopods as protected animals. Regulated procedures include acts that may cause pain, suffering, distress or lasting harm to animals. Animal testing is often cited by some in the industry as being necessary for various purposes, including drug development, veterinary medicines, and chemical or environmental safety testing. However, we have already made movements away from it, for example in the 1998 ban on testing of beauty products and cosmetics, and in a recent written answer, the Government confirmed that there are no laws mandating its use. Nevertheless, we are still in a very challenging situation, and these practices continue.

I want to reiterate some of the data that we spoke about last year. In 2021, over 3 million scientific procedures were conducted on animals. If that number were not bad enough, that was actually an increase on previous years—an increase in the use of dogs by 3%, of cats by 6%, of horses by 29% and of monkeys by 17%. We can only speculate why the number increased, but that certainly does not tie in with the messages we hear that the use of NAMs is on the up and the use of animals on the down.

The issue is not just that these procedures are happening to animals, but the awful conditions that animals are often kept in while waiting for procedures to be done to them. A recent report from the Animals in Science Regulation Unit described “deeply troubling” animal welfare standards in British laboratories between 2019 and 2021. I am sure that many of us will have received emails containing pictures and videos of some of those procedures. I have seen some pretty awful things that are happening to animals here in the UK, despite the industry telling us that it upholds the highest possible animal welfare standards. Failings include a non-human primate dying after becoming trapped behind a restraint device; 112 rats being crushed alive when they were moved in error to a compactor; and numerous incidents of animals being left without water or food.

As I said, the UK purports to be a nation of animal lovers, and I truly believe that it is, but we need to ensure that we update our laws to truly reflect that fact. I acknowledge that efforts are being made to promote NAMs—including cell cultures, human tissues, computer modelling and volunteer studies—and that organisations are trying to invest in and improve the use of NAMs to reduce reliance on animal testing. However, I want to pay particular attention to the second of the two petitions that we are debating, which relates specifically to dogs.

Dogs are most commonly used in secondary species testing. That is where a test on an animal, normally a mouse or rat, has already been conducted but some researchers go on to conduct a secondary test on a different species, and dogs are commonly cited as animals used for that. However, the industry itself says that that is almost completely unnecessary now. Companies such as Pfizer and AstraZeneca have stood up at global health forums and said, “We don’t want to do secondary species testing any more. Please help us find the road map to get us out of the need to do this.”

[Virginia Crosbie (Ynys Môn) (Con)]

I thank my hon. Friend for allowing me to intervene; he is making a passionate speech on such an important matter. My constituency is Ynys Môn, and we are an island of animal lovers—animals ranging from dolphins and red squirrels to sheep and cattle and our feline and canine friends—so it is no surprise that many of my constituents actively campaign for the rights of animals and support reducing the use of animals in scientific experiments. They and I would like to know what steps the Government are taking to support the pharmaceutical industry in the development and use of non-animal testing models.

[Elliot Colburn]

I am grateful to my hon. Friend for that intervention; I think that more than 100 of her constituents signed this petition too. I hope that the Minister heard her request—indeed, I am sure that it is an ask of all of us in the Chamber today. What is being done, and what more can be done, to try to encourage people out of using animals and into using non-animal methods?

I want to pick up again the point about animal welfare. Many people will cite the regulations that are in place in the UK for animals in experiment environments. However, this statistic might shed some light on why welfare standards are so low. As of 2021, there were only an estimated 23 full-time equivalent inspectors in the United Kingdom. That is 23 inspectors trying to look at 3 million different procedures. The fact that so much self-reporting is going on in the industry and there are so few inspectors leads, again, to the argument that non-animal methods are a much better use of money and bring with them higher ethical and moral standards.

I want to go through some of the proposed solutions before I hand over to some of my colleagues. PETA—People for the Ethical Treatment of Animals—has proposed a solution known as the research modernisation deal, or RMD, which offers a strategy to eliminate the use of animals in biomedical research, regulatory testing and education. It prioritises non-animal methods, conducts critical reviews to assess the necessity of animal use, and reallocates funds to non-animal methods. This is aimed specifically at making the UK once again a leader in innovative, ethical scientific practices. Furthermore, we have seen advances in technology such as in vitro and in silico tests, and innovative technologies such as organs on chips, which offer higher levels of protection and prediction accuracy.

[Caroline Nokes (Romsey and Southampton North) (Con)]

rose—

[Elliot Colburn]

That is one of the things I want to stress, but before I do so, I will give way to the Chair of the Women and Equalities Committee.

[Caroline Nokes]

My hon. Friend makes the really important point that non-animal methods can be much more accurate than using animals in these experiments. Does he agree that companies such as Lush, which came to Parliament before Christmas to advocate for those methods, have shown the way in which, through science, we can do better?

[Elliot Colburn]

I absolutely agree with my right hon. Friend. This is something that we cannot stress enough in this debate: it has been proven in the data time and again that non-animal methods are highly accurate, and much more accurate when it comes to predicting human responses than animal testing is. In fact, animal testing has such low levels of success when it comes to measuring how a drug or something else might affect a human that we would not accept that in any other form of business. When the levels of prediction are so poor, why are we still accepting it? It does not make any sense—not when we have alternatives that can offer much greater clarity about to how humans will react to products and drugs.

However, there are challenges standing in the way, and one of them remains funding for NAMs. Pfizer and AstraZeneca have said that they do not want to do things such as secondary species testing, but regulatory guidelines often expect new drugs to be tested on animals and there is a lack of consensus on possible transition timelines. There is also push-back from the industry, which is resistant to change. However, in advance of this debate I spoke to many scientists and industry leads who said they are crying out for change and want to be at the forefront of non-animal methods. We need to give them the tools to do so and look at the way we fund research.

[Dr Lisa Cameron (East Kilbride, Strathaven and Lesmahagow) (Con)]

My hon. Friend is making a fantastic speech. He is standing up for all the animals that do not have a voice in the industry and speaking for those across the UK who want to support them. Several organisations contacted me and talked about the need for change. They said that we must look after animals—particularly beagle pups—post testing where possible, but they pointed out that the industry has been very resistant to engaging with rehoming centres, even when the beagle pups have not undergone lethal testing. Surely we can do better. Whenever an animal can have a life in a loving home afterwards, we must make that happen.

[Elliot Colburn]

My hon. Friend is absolutely right, and I hope the Minister heard that.

Commercial breeding—in particular, of beagles—is hard for this country to accept. The data shows that a lot of such testing, if not all of it, is unnecessary because the accuracy of the tests is so low. Given that secondary species tests on dogs seem so unnecessary, why are we still allowing them to happen?

Since the debate last year, there has been some welcome news internationally: Canada, Australia and countries within the European Union have come up with road maps for ending animal testing. It is critical that we ask the Government to consider how we do that. We need a strategy and a road map to work with the industry, campaign groups, charities, other organisations and the people who are in the Public Gallery today, to move us away from the use of animals and towards non-animal methods as the default standard. I appreciate that some countries have found it difficult to come up with precise timelines because of disagreements within the sector, but that does not mean we should not try. That is the key thing to take away from this debate.

There are things that we can do in the immediate and interim terms, one of which is to look at animal welfare standards. Twenty-three people looking at 3 million procedures simply is not enough. We also need an immediate review of the necessity of secondary species testing. Whatever happens next, it is imperative that we prioritise the development and adoption of non-animal research methods. The fact the number of scientific procedures conducted on animals went up in 2021—we actually stopped collecting data after that point, so we are not entirely sure how many we are doing, which I think is a mistake—demonstrates that there is not enough impetus behind the agenda of moving towards non-animal methods.

I ask the Government to invest in and fund NAMs properly by reallocating existing funds and promoting collaboration. They have an incredible ability to bring together the industry, researchers, advocacy groups, campaigners and others to create a road map and a strategy so we can truly say that the UK does not need to use animal testing methods any more. We can stop the use of animals and hold ourselves up to an incredibly high international standard as a nation of animal lovers.

--- Later in debate ---

[Elliot Colburn]

Do not worry, Dame Caroline; I do not intend to take the full remaining hour and a half to wind up. I thank the petitioners for bringing this topic to the House for us to debate, and I thank colleagues for their contributions.

I want to clarify for the record something I said earlier about the non-publication of data. I was referring to detailed information on procedures by establishment type—in other words, whether the venture is a commercial or an academic one—which ceased being published in 2021, and the annual publication of technical summaries for project licences that are granted. I may have inadvertently suggested that we stopped publishing data on how many procedures took place; I just want to clarify that that is not the case.

I thank again all the organisations, campaign groups, charities and others, many of whom are represented in the Public Gallery, for briefing me and colleagues in advance of today’s debate. I thank in particular my right hon. Friend the Member for Camborne and Redruth (George Eustice), who made an incredibly detailed and knowledgeable contribution, and my hon. Friend the Member for Chatham and Aylesford (Tracey Crouch). I particularly enjoyed her description of her “melting in a mess of complexity”—a great Tinder profile if ever I heard one. I will certainly be investing in that.

I thank the Minister for his response. Regulars at petitions debates will know how frustrating it is to come here only to hear a response stating why the status quo is to continue; it is rare that we leave with nuggets of future policy. The restarting of the public attitudes survey, the doubling of investment next year, the Home Office review of licence duration and fees, and that all-important plan are excellent steps in the right direction. I am grateful that he was able to make some announcements during the debate, and I am sure that the organisations that are represented in the Public Gallery and that briefed Members will want to engage with the Department for Science, Innovation and Technology in order to feed into the plan. I am very grateful for that announcement. As we have made clear, if we do not make any progress, we will be back next year talking about exactly the same thing, because that is what the petitioners expect of us.

Question put and agreed to.

Resolved,

That this House has considered e-petitions 633591 and 645885 relating to animal testing and non-animal research methods.